Buy & Sell Constellation Energy Corporation (CEG) – Constellation Energy Corporation Price Today
Aura AI Summary
Key Stats
- $91.00BMarket Cap
- EnergySector
- -21.1%3M Drawdown
- $112.67BEnterprise Value
- 0.67%Dividend Yield
- 20 daysTypical Hold Time
Constellation Energy Corporation (CEG) is currently valued at a market capitalization of $91.00B, with an enterprise value of $112.67B. Over the past 52 weeks, Constellation Energy Corporation has traded between a low of $247.06 and a high of $403.95, highlighting its annual price range. Over the past three months, Constellation Energy Corporation has recorded a drawdown of -21.1%, reflecting recent price volatility. Constellation Energy Corporation offers a dividend yield of 0.67%, with the most recent dividend of $0.43 paid on 15 May 26. On average, investors hold Constellation Energy Corporation for approximately 20 days, indicating typical investor behavior on the platform.
About Constellation Energy Corporation
Constellation is the largest producer of carbon-free energy in the U.S. and a leading nuclear power plant operator. It provides sustainable electricity to millions of residential, public, and industrial customers.
Most Recent News
Cyabra inks $500K+ deal to fight online hate with AI-powered disinformation detection for global research institute
Cyabra, an AI-driven disinformation intelligence company, has secured a contract worth over $500,000 to provide its technology to a leading international research institute focused on tracking global hate speech. The platform will help identify coord...

Ormat launches Ormega100, the largest binary geothermal unit, to boost Enhanced Geothermal System deployment.
Ormat Technologies introduced the Ormega100, the industry's largest binary power generation unit delivering 100 MW output, designed to accelerate commercialization and scaling of Enhanced Geothermal Systems (EGS). With 60 years of expertise and exten...

ADARx to present Phase 1/2 data on Onvuzosiran for hereditary angioedema at 2026 EAACI Congress
ADARx Pharmaceuticals announced it will present Phase 1/2 clinical data for Onvuzosiran, an RNA therapy for hereditary angioedema (HAE), at the 2026 EAACI Congress in Istanbul. Onvuzosiran targets plasma prekallikrein to prevent swelling attacks by r...
